ADC Ther­a­peu­tics has raised $550M-plus in its quest for their first BLA — and here’s why that’s im­por­tant

The mon­ey train con­tin­ues to chug in bio­phar­ma.

ADC Ther­a­peu­tics has added one last batch of cash to its E round — a 2-year fundrais­ing af­fair that is now be­ing closed at $303 mil­lion. The mon­ey will fund a dri­ve to their first planned BLA for their lead an­ti­body-drug con­ju­gate next year, with one piv­otal study ful­ly en­rolled and an­oth­er on the way.

ADC ini­tial­ly put to­geth­er a $200 mil­lion round for the piv­otal work, then added an ex­ten­sion that to­tals $103 mil­lion — slip­ping in $25 mil­lion from an un­named “U.S.-based in­sti­tu­tion­al in­vestor, as well as ad­di­tion­al in­vest­ment from ex­ist­ing in­vestors that par­tic­i­pat­ed in the pre­vi­ous­ly an­nounced $76 mil­lion Se­ries E fi­nanc­ing ex­pan­sion.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.